Keryx Biopharmaceuticals (NASDAQ:KERX) : 6 brokerage houses believe that Keryx Biopharmaceuticals (NASDAQ:KERX) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Keryx Biopharmaceuticals (NASDAQ:KERX). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 9 Wall Street Analysts endorse the stock as a Buy with a rating of 1.56.
Keryx Biopharmaceuticals (NASDAQ:KERX) : Currently there are 8 street experts covering Keryx Biopharmaceuticals (NASDAQ:KERX) stock. The most bullish and bearish price target for the stock is $13 and $4 respectively for the short term. The average price target of all the analysts comes to $8.75. The estimated standard deviation from the target is $2.92.
For the current week, the company shares have a recommendation consensus of Buy.
Keryx Biopharmaceuticals (NASDAQ:KERX): stock turned positive on Tuesday. Though the stock opened at $5.94, the bulls momentum made the stock top out at $6.3 level for the day. The stock recorded a low of $5.91 and closed the trading day at $6.22, in the green by 7.61%. The total traded volume for the day was 1,479,043. The stock had closed at $5.78 in the previous days trading.
In an insider trading activity, Madison Greg, director officer (President and CEO) of Keryx Biopharmaceuticals Inc, unloaded 1,873 shares at an average price of $5.42 on May 9, 2016. The total amount of the transaction was worth $10,152, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of products for the treatment of renal diseases. Its lead product Auryxia (ferric citrate), an oral, absorbable iron-based compound, received marketing approval from the United States Food and Drug Administration (FDA), for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis. The approval of Auryxia was based on data from its Phase III registration program, in which Auryxia effectively reduced serum phosphorus levels to well within the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines range of 3.5 to 5.5 mg/dL. In addition to the effects on serum phosphorus levels, Auryxias pharmacodynamic properties resulted in increased ferritin, iron and transferrin saturation (TSAT).